Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
Perioperative durvalumab plus neoadjuvant chemotherapy led to significant improvements in event-free survival and overall survival as compared with neoadjuvant chemotherapy alone. (Funded by AstraZeneca; NIAGARA ClinicalTrials.gov number, NCT03732677; EudraCT number, 2018-001811-59.).
Authors
- Lorenzo Antonuzzo (ORCID: https://orcid.org/0000-0003-3349-5604)
- Joshua J. Meeks (ORCID: https://orcid.org/0000-0002-5444-5510)
- Matthew D. Galsky (ORCID: https://orcid.org/0000-0001-7655-9378)
- Stephan Hois
- Hikmat A Al‐Ahmadie (ORCID: https://orcid.org/0000-0002-2938-6627)
- Mustafa Özgüroğlu (ORCID: https://orcid.org/0000-0002-8417-8628)
- Michiel S. van der Heijden (ORCID: https://orcid.org/0000-0002-4407-7881)
- James W.F. Catto (ORCID: https://orcid.org/0000-0003-2787-8828)
- Vagif Atduev (ORCID: https://orcid.org/0000-0003-4478-7282)
- Yousef Zakharia (ORCID: https://orcid.org/0000-0001-9480-2626)
- Toan Quang Vu
- Ashok Kumar Gupta (ORCID: https://orcid.org/0000-0002-2282-7266)
- Ariel Galapo Kann (ORCID: https://orcid.org/0000-0002-7260-2030)
- Hiroyuki Nishiyama (ORCID: https://orcid.org/0000-0001-7423-596X)
- Thomas Powles
- Cristina Suárez (ORCID: https://orcid.org/0000-0002-0502-5528)
- Florian Roghmann
- J. Armstrong (ORCID: https://orcid.org/0009-0008-2292-1835)
- Moran Gadot (ORCID: https://orcid.org/0000-0002-9832-9175)
- Tomáš Büchler (ORCID: https://orcid.org/0000-0001-6667-994X)
- Paweł Wiechno (ORCID: https://orcid.org/0000-0002-4894-3273)
- Bernhard J. Eigl (ORCID: https://orcid.org/0000-0003-1653-6929)
- Niara Oliveira (ORCID: https://orcid.org/0000-0001-7103-2200)
- Tae‐Hwan Kim (ORCID: https://orcid.org/0000-0002-3542-2276)
- Chao-Hsiang Chang
Institutions
- Queen Mary University of London (GB)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2024-09-15
- DOI
- https://doi.org/10.1056/nejmoa2408154
- Citations
- 274
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 156.94
Funders
- AstraZeneca